VK gene segments and CDR3-deduced amino acid sequences of HCV-associated NHLs and homology to protein sequence databases
| Patient no. . | IgK CDR3–deduced amino acid sequences . | Length of CDR3 AA . | Sequences producing the highest significant similarity . | E value5-150 . | Vkfamily/gene . | Jk segment . |
|---|---|---|---|---|---|---|
| 1 | CQQYGSSRTFGQGTKLEIK | 19 | anti-HCV/RF-CUR | 0.003/0.011 | VKIII-kv325 | JKI |
| 2 | CQQYGSSPYTFGQGTKLEIKR | 21 | RF-FLO/anti-HCV | 4e-06/2e-04 | VKIII-kv325 | JK2 |
| 3 | CQQYGSSPYTFGQGTKL | 17 | RF/anti-HCV | 7e-04/0.006 | VKIII-kv325 | JK2 |
| 4 | CQQYGSSPYTFGQGTKVEI | 19 | RF-FLO/anti-HCV | 1e-04/2e-04 | VKIII-kv325 | JK2 |
| 5 | CQHYNNWPPWTFGQGTKLEIK | 21 | RF-WA | 6e-07 | VKIII-kv328h5 | JKI |
| 6 | ND | ND | ||||
| 7 | CQQYGSSPRTFGQGTKL | 17 | anti-HCV/RF-CUR | 0.001/0.003 | VKIII-kv325 | JKI |
| 8 | ND | ND | VKII | |||
| 9 | ND | ND | ||||
| 10 | CQQYNNWPPWTFGPGTKVKSNR | 22 | RF-4C9 | 5e-06 | VKIII-kv328h5 | JKI |
| 11 | CQQYNIYPYTFGQGTKLEIKREY | 23 | RF-FLO | 5e-04 | VKI-L12a | JK2 |
| 12 | CQQYGSSPTFGQGTKL | 16 | anti-HBV/anti-HCV/RF-FLO | 0.073/0.12/0.12 | VKIII-kv325 | JKI |
| 13 | CLQYNSYPRTFGQGTKVEIK | 20 | anti-GPIIb/anti-CMV | 5e-04/7e-04 | VKI-A30 | JKI |
| 14 | CQQYNNWPPWTFGQGTKVEIK | 21 | RF-WA | 7e-08 | VKIII-kv328h5 | JKI |
| 15 | ND | ND | VKII | |||
| 16 | CQQYGSSPRTFGQGTKVEI | 19 | RF-CUR/anti-HCV | 1e-04/2e-04 | VKIII-kv325 | JKI |
| 17 | ND | ND |
| Patient no. . | IgK CDR3–deduced amino acid sequences . | Length of CDR3 AA . | Sequences producing the highest significant similarity . | E value5-150 . | Vkfamily/gene . | Jk segment . |
|---|---|---|---|---|---|---|
| 1 | CQQYGSSRTFGQGTKLEIK | 19 | anti-HCV/RF-CUR | 0.003/0.011 | VKIII-kv325 | JKI |
| 2 | CQQYGSSPYTFGQGTKLEIKR | 21 | RF-FLO/anti-HCV | 4e-06/2e-04 | VKIII-kv325 | JK2 |
| 3 | CQQYGSSPYTFGQGTKL | 17 | RF/anti-HCV | 7e-04/0.006 | VKIII-kv325 | JK2 |
| 4 | CQQYGSSPYTFGQGTKVEI | 19 | RF-FLO/anti-HCV | 1e-04/2e-04 | VKIII-kv325 | JK2 |
| 5 | CQHYNNWPPWTFGQGTKLEIK | 21 | RF-WA | 6e-07 | VKIII-kv328h5 | JKI |
| 6 | ND | ND | ||||
| 7 | CQQYGSSPRTFGQGTKL | 17 | anti-HCV/RF-CUR | 0.001/0.003 | VKIII-kv325 | JKI |
| 8 | ND | ND | VKII | |||
| 9 | ND | ND | ||||
| 10 | CQQYNNWPPWTFGPGTKVKSNR | 22 | RF-4C9 | 5e-06 | VKIII-kv328h5 | JKI |
| 11 | CQQYNIYPYTFGQGTKLEIKREY | 23 | RF-FLO | 5e-04 | VKI-L12a | JK2 |
| 12 | CQQYGSSPTFGQGTKL | 16 | anti-HBV/anti-HCV/RF-FLO | 0.073/0.12/0.12 | VKIII-kv325 | JKI |
| 13 | CLQYNSYPRTFGQGTKVEIK | 20 | anti-GPIIb/anti-CMV | 5e-04/7e-04 | VKI-A30 | JKI |
| 14 | CQQYNNWPPWTFGQGTKVEIK | 21 | RF-WA | 7e-08 | VKIII-kv328h5 | JKI |
| 15 | ND | ND | VKII | |||
| 16 | CQQYGSSPRTFGQGTKVEI | 19 | RF-CUR/anti-HCV | 1e-04/2e-04 | VKIII-kv325 | JKI |
| 17 | ND | ND |
Smallest sum probability according to the BLAST similarity search program. The E value is inversely related to statistical significance and is considered significant for a value below 0.05.
ND indicates not determined.
Genbank accession numbers for anti E2 protein of HCV: AJ236554 for patients 1 and 12, AJ236552 for patients 2, 3, and 4, and AJ236551 for patients 7 and 16; RF-CUR: prf1206991A; RF-FLO: prf1714186A for patient 2 and prf1206991B for patients 4, 11, and 12; RF: prf1714186A; RF-WA:U03401; RF-4C9: L48238; anti-HBV: M88319; anti-GPIIIb: S73911; anti-CMV: L26893.